Heparin rescues factor v Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model

Blood

Volumn 121, Issue 11, 2013, Pages 2127-2134

  An, Jianzhong ^a   Waitara, Magarya S ^a   Bordas, Michelle ^a   Arumugam, Vidhyalakshmi ^a   Hoffmann, Raymond G ^a   Petrich, Brian G ^b   Sinha, Uma ^c   North, Paula E ^a,d   Sood, Rashmi ^a,d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Portola Pharmaceuticals Inc   (United States)

^d Children's Hospital of Wisconsin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ENOXAPARIN; FONDAPARINUX; HIRUDIN; LEPIRUDIN; PROTEINASE ACTIVATED RECEPTOR 3; THROMBIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; HEPARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BREEDING; CONTROLLED STUDY; EMBRYO; FEMALE; FETUS; FETUS WASTAGE; GENOTYPE; GROWTH RETARDATION; HIGH RISK PREGNANCY; MALE; MOUSE; NONHUMAN; PLACENTA FUNCTION; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOPHILIA; THROMBOPLASTIN TIME; ANIMAL; ANIMAL EMBRYO; BLOOD; BLOOD CLOTTING; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; EVALUATION; GENETICS; HUMAN; MOUSE MUTANT; PHYSIOLOGY; PLACENTA DISORDER; PREGNANCY; PREGNANCY COMPLICATION;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; FACTOR V; FEMALE; HEPARIN; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLACENTA DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY, HIGH-RISK;

MLCS; MLOWN;

EID: 84877593502     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-448209     Document Type: Article

References (50)

1. Ngoc NT, Merialdi M, Abdel-Aleem H, et al. Causes of stillbirths and early neonatal deaths: Data from 7993 pregnancies in six developing countries. Bull World Health Organ. 2006;84(9): 699-705.
2. Barker DJ, Osmond C, Kajantie E, et al. Growth and chronic disease: Findings in the Helsinki Birth Cohort. Ann Hum Biol. 2009;36(5):445-458.
3. Benedetto C, Marozio L, Tavella AM, et al. Coagulation disorders in pregnancy: Acquired and inherited thrombophilias. Ann N Y Acad Sci. 2010; 1205:106-117.
4. Robertson L, Wu O, Langhorne P, et al. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: A systematic review. Br J Haematol. 2006;132(2):171-196.
5. Brenner B, Hoffman R, Carp H, et al; LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: The LIVE-ENOX study. J Thromb Haemost. 2005;3(2):227-229.
6. Gris JC, Mercier E, Quéré I, et al. Low-molecularweight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695-3699.
7. de Vries JI, van Pampus MG, Hague WM, et al; FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: The FRUIT-RCT. J Thromb Haemost. 2012;10(1):64-72.
8. Gris JC. LMWH have no place in recurrent pregnancy loss: Debate-against the motion. Thromb Res. 2011;127(suppl 3)S110-112.
9. Lindqvist PG, Merlo J. Low molecular weight heparin for repeated pregnancy loss: Is it based on solid evidence?. J Thromb Haemost. 2005;3(2): 221-223.
10. Middeldorp S. Low-molecular-weight heparins have no place in recurrent miscarriage: Debate- for the motion. Thromb Res. 2011;127(suppl 3) S105-109.
11. Walker ID, Kujovich JL, Greer IA, et al. The use of LMWH in pregnancies at risk: new evidence or perception?. J Thromb Haemost. 2005;3(4):778-793.
12. Sikkema JM, Franx A, Bruinse HW, et al. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta. 2002;23(4): 337-342.
13. Morssink LP, Santema JG, Willemse F. Thrombophilia is not associated with an increase in placental abnormalities in women with intrauterine fetal death. Acta Obstet Gynecol Scand. 2004;83(4):348-350.
14. Rogers BB, Momirova V, Dizon-Townson D, et al. Avascular villi, increased syncytial knots, and hypervascular villi are associated with pregnancies complicated by factor V Leiden mutation. Pediatr Dev Pathol. 2010;13(5):341-347.
15. Rodger MA, Paidas M. Do thrombophilias cause placenta-mediated pregnancy complications? Semin Thromb Hemost. 2007;33(6):597-603
16. Gris JC. Thrombophilia and pregnancy loss: Cause or association. Thromb Res. 2009; 123(suppl 2)S105-110.
17. Kingdom JC, Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies?. Blood. 2011;118(18):4780-4788.
18. Georgiades P, Ferguson-Smith AC, Burton GJ. Comparative developmental anatomy of the murine and human definitive placentae. Placenta. 2002;23(1):3-19.
19. Sood R, Kalloway S, Mast AE, et al. Fetomaternal cross talk in the placental vascular bed: Control of coagulation by trophoblast cells. Blood. 2006; 107(8):3173-3180.
20. Sood R, Zogg M, Westrick RJ, et al. Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med. 2007;204(5):1049-1056.
21. Cornelissen I, Palmer D, David T, et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci USA. 2010;107(43):18605-18610.
22. Petrich BG, Fogelstrand P, Partridge AW, et al. The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation. J Clin Invest. 2007; 117(8):2250-2259.
23. Sinha U, Ku P, Malinowski J, et al. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur J Pharmacol. 2000;395(1):51-59.
24. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23(1):17-25.
25. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost. 2003;1(6):1258-1263.
26. Betz A, Wong PW, Sinha U. Inhibition of factor Xa by a peptidyl-alpha-ketothiazole involves two steps. Evidence for a stabilizing conformational change. Biochemistry. 1999;38(44):14582-14591.
27. Erez O, Gotsch F, Mazaki-Tovi S, et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med. 2009;22(8):672-687.
28. Romero R, Copel JA, Hobbins JC. Intrauterine fetal demise and hemostatic failure: The fetal death syndrome. Clin Obstet Gynecol. 1985; 28(1):24-31.
29. Sambrano GR, Huang W, Faruqi T, et al. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000; 275(10):6819-6823.
30. Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem. 2006;281(43): 32095-32112.
31. Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood. 2012;119(8):e45-e56.
32. Li W, Zheng X, Gu JM, et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood. 2005;106(8):2716-2722.
33. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003; 9(3):331-337.
34. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998;101(9):1983-1991.
35. Castellino FJ, Liang Z, Volkir SP, et al. Mice with a severe deficiency of the endothelial protein C receptor gene develop, survive, and reproduce normally, and do not present with enhanced arterial thrombosis after challenge. Thromb Haemost. 2002;88(3):462-472.
36. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222-1226.
37. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112(11): 1644-1654.
38. Koenig A, Norgard-Sumnicht K, Linhardt R, et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101(4):877-889.
39. Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006;95(3):535-540.
40. Drewlo S, Levytska K, Sobel M, et al. Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling. J Thromb Haemost. 2011;9(12): 2486-2497.
41. Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to heparin. Obstet Gynecol. 2011;117(6):1375-1383.
42. André P, LaRocca T, Delaney SM, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation. 2003;108(21):2697-2703.
43. Bikfalvi A. Platelet factor 4: An inhibitor of angiogenesis. Semin Thromb Hemost. 2004; 30(3):379-385.
44. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-285.
45. Zaslavsky A, Baek KH, Lynch RC, et al. Plateletderived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 2010;115(22):4605-4613.
46. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placentalmediated complications of pregnancy in women without thrombophilia: A pilot randomized controlled trial. J Thromb Haemost. 2009;7(1): 58-64.
47. Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011; 106(6):1053-1061.
48. Martinelli I, Ruggenenti P, Cetin I, et al; HAPPY Study Group. Heparin in pregnant women with previous placenta-mediated pregnancy complications: A prospective, randomized, multicenter, controlled clinical trial. Blood. 2012; 119(14):3269-3275.
49. Clark P, Walker ID, Langhorne P, et al; Scottish Pregnancy Intervention Study (SPIN) collaborators. SPIN (Scottish Pregnancy Intervention) study: A multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115(21): 4162-4167.
50. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010; 362(17):1586-1596.